MnDPDP: Contrast Agent for Imaging and Protection of Viable Tissue

Figure 14

MnDPDP as cytoprotective adjunct to chemotherapy. Patients with advanced cancer of colon were treated with repeated cycles with oxaliplatin as primary anticancer drug and MnDPDP as adjunct for protection of normal tissues. (a) Adverse events (AEs) [23]. AEs of grade I (mild), II (moderate), III (severe), and IV (life-threatening) were recorded in 14 patients during 3 therapy cycles with oxaliplatin and with preinfusion of MnDPDP 2 μmol/kg or saline (placebo). There was a major reduction in AEs grade II-IV with MnDPDP. Also plasma leukocyte content was maintained at a higher level with MnDPDP (reprinted with permission from Translational Oncology). (b) Peripheral sensory neuropathy (PSN) [24]. Patients that experienced PSN during previous oxaliplatin cycles were followed for up to 8 further cycles, each with preinfusion of MnDPDP 5 μmol/kg. In these cycles, MnDPDP gradually reduced the initial severity of PSN (black > dark gray > light gray) indicating a reversal of the underlying nerve injuries (reprinted with permission from J Clin Invest). (c) Plasma [Mn] (nmol/L) during therapy with oxaliplatin and MnDPDP [24]. Patients cited in B showed a gradual rise in plasma [Mn] over 8 cycles in 4 months without exceeding normal levels of 10–20 nmol/L [29, 33] (reprinted with permission from J Clin Invest).